RxDoctor Payments Data

Jeani Buhl

Nurse Practitioner · Medford, ORNPI 1790755031

Payments from drug & device makers

$775in general payments, 2019–2025

Across 25 payments — averaging $31.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$255
  • Johnson & Johnson$199
  • Takeda Pharmaceuticals U.S.A., Inc.$120
  • Gilead$60
  • Madrigal Pharmaceuticals$44
  • Regeneron Healthcare Solutions, Inc.$38
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$69590%
  • Education$8010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$775 in reported general payments places this provider in the 90th percentile of 997 nurse practitioner providers in Oregon.

See all nurse practitioner providers in Oregon

Medicare billing

Part B allowed, 2024
$55,004
Medicare patients
530
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab87$785,628
StelaraUstekinumab22$588,469
XifaxanRifaximin52$164,971
ZenpepLipase/Protease/Amylase24$81,083
CreonLipase/Protease/Amylase35$72,197
Mesalamine80$53,446
LinzessLinaclotide43$27,881
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates180$12,121
MotegrityPrucalopride Succinate12$6,159
Budesonide DrBudesonide51$6,117
Dexlansoprazole DrDexlansoprazole15$5,368
Ursodiol47$5,266
Sucralfate38$4,912
Budesonide EcBudesonide11$4,444
Omeprazole298$4,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$199$588,46922 claims
AbbVieCreon, Linzess$255$100,07878 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$120$6,15912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 997 nurse practitioner providers in Oregon.

Other nurse practitioner in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →